Here's Why Zoetis (ZTS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The animal health industry is resilient, Zoetis CEO
Zoetis CEO Kristin Peck unpacks pet owners' concerns in caring for their beloved animals on 'The Claman Countdown.'
Zoetis: Healing Paws, Growing Profits
Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has growing revenues, a strong balance sheet, a high FCF margin, and no major maturities. Li...
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)
Zoetis Inc. (NYSE:ZTS ) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen ...
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spend...
Zoetis Q3: Strong Osteoarthritis Pain Franchise
I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA an...
Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants...
Zoetis raises full-year guidance on strong Q3 results
Zoetis Inc (NYSE:ZTS, ETR:ZOE) delivered another impressive quarter, with revenue and earnings exceeding Wall Street estimates for the third quarter of fiscal year 2024. For the period ended Septem...
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc....
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
Zoetis (ZTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the most recent trading session, Zoetis (ZTS) closed at $191.09, indicating a +0.2% shift from the previous trading day.
Zoetis Inc (ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Zoetis Inc (NYSE:ZTS ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 1:05 PM ET Company Participants Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financ...
The Schall Law Firm Is Looking Into Securities Violations By Zoetis Inc And Urges Investors To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ...
Related Companies